Prevalence of drug-drug interactions in cancer patients treated with anti-cancer drugs.

No registrations found.

Ethical review	Positive opinion
Status	Pending
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON22087

Source
NTR

Brief title
N/A

Health condition

Cancer, chemotherapy, drug-drug interactions, oncology, pharmacology, risk factors.

Sponsors and support

Primary sponsor: Erasmus University Medical Center
Source(s) of monetary or material Support: 1.Erasmus University Medical Center 2.Stichting Coolsingel

Intervention

Outcome measures

Primary outcome

Prevalence of drug-drug interactions (DDI's) and the clinical consequence of these DDI's.

Secondary outcome

The secondary objective is to obtain more insight into possible determinants for the occurrence of these DDIs.

Study description

Background summary

Drug-drug interactions in patients using anticancer drugs are common, although not always these are recognized by pharmacists and physicians. These interactions may have serious consequences for the number and severity of side-effects and efficacy of treatment. As side-effects could potentially be lethal, and efficacy could be diminished by such interactions, it is extremely important to visualize drug-drug interactions (DDI) on forehand. With a firm increase in available (and chronically used) oral anticancer agents during recent years, the risk for DDIs has become even more important for clinical practice. Outcomes of this study may help physicians and pharmacists to create awareness of DDIs and should lead to a closer collaboration between them to identify and manage these DDIs.

Study objective

We assess the prevalence and seriousness of DDIs among ambulatory cancer patients on anti-cancer treatment.

Study design

1-2-2012: Start study inclusion;

1-2-2013: End study inclusion;

1-2-2013 till 1-2-2013: Analysing, writing.

Intervention

Medication review in oncology.

Contacts

Public

Erasmus University Medical Center, Department of Pharmacy
´s-Gravendijkwal 230

Roelof Leeuwen, van
Rotterdam 3015 CE
The Netherlands
+31 (0)10 7033202
Scientific
Erasmus University Medical Center, Department of Pharmacy
´s-Gravendijkwal 230
Roelof Leeuwen, van
Rotterdam 3015 CE
The Netherlands
+31 (0)10 7033202

Eligibility criteria

Inclusion criteria

All ambulatory patients with the diagnosis of a solid tumour or a haematological malignancy, who are receiving one or more (oral) anti-cancer therapies, are included in the study.

Exclusion criteria

1. The use of experimental trial agents;

2. Age <18 years;

3. The use of anti-cancer drugs for non-malignant diseases.

Study design

Design

Study type:	Observational non invasive
Intervention model:	Parallel
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

NL

Recruitment status:	Pending
Start date (anticipated):	01-02-2013
Enrollment:	500
Type:	Anticipated

Ethics review

Positive opinion

Date:	19-12-2012
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL3591
NTR-old	NTR3760
Other	METC : 12.12151
ISRCTN	ISRCTN wordt niet meer aangevraagd.

Study results

Summary results

N/A